Research site

Niepubliczny Zaklad Opieki Zdrowotnej Salmed

Poland Ul. Waclawa Jawoszka 3, 21-010 Leczna, Poland

2 trials recruiting
Colitis ulcerative · Crohn's disease · Pneumococcal immunisation
Adults and children

About Specializations

Niepubliczny Zaklad Opieki Zdrowotnej Salmed in Leczna, Poland specialises in clinical trials of conditions such as Colitis ulcerative, Crohn's disease, Pneumococcal immunisation, Influenza, and other specialisations. This site conducts important research.

Main research areas of the site

Bacterial Infections and Mycoses

At Niepubliczny Zaklad Opieki Zdrowotnej Salmed, the research team is dedicated to preventing meningococcal infection by evaluating new vaccine options for young children.

Development of a conjugate vaccine targeting serogroups A, C, W, and Y
Assessment of immunogenicity in infants and toddlers
Safety monitoring in healthy volunteers
Comparison of antibody responses to an established vaccine

The ongoing studies aim to demonstrate non‑inferior immune protection using geometric mean titers as a measure of response, while also confirming the safety profile of the investigational MenACYW conjugate vaccine in this pediatric population.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Ul. Waclawa Jawoszka 321-010 LecznaPoland

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 9

More sites in Leczna Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

12 clinical trials

Crohn's disease

Recruiting

Investigational

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Ro7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Influenza

Recruiting

Registered drugNo placebo

Study on Baloxavir Marboxil for Children with Influenza

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Baloxavir Marboxil
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Pneumococcal immunisation

Not yet recruiting

Registered drugNo placebo

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
Sponsor:Pfizer Inc.

Contact Research Centre

Pneumococcal immunisation

Not yet recruiting

Registered drugNo placebo

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Poland

Participants:0–17 years
Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
Sponsor:Pfizer Inc.

Contact Research Centre

Coagulopathy

Not recruiting

Registered drugNo placebo

Study on the Effectiveness of Human Coagulation Factor IX and Drug Combination for Patients with Major Bleeding on Factor Xa Inhibitor Therapy

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Protein C
Sponsor:Octapharma AG

Contact Research Centre

Colitis ulcerative+1

Not recruiting

Investigational

Study on the Effects of TEV-48574 for Adults with Moderate to Severe Ulcerative Colitis or Crohn's Disease

Investigational

Poland

Participants:18–64 years · 65+ years
Substances:Duvakitug
Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Contact Research Centre

Colitis ulcerative

Not recruiting

Registered drug

A study to evaluate the efficacy and safety of vixarelimab in patients with moderate to severe ulcerative colitis

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Adalimumab
Sponsor:Genentech Inc.

Contact Research Centre

Pneumococcal infection

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of PF-07831695 and a Drug Combination for Pneumococcal Infections in Healthy Toddlers Aged 12-15 Months

Registered drugNo placebo

Poland

Participants:0–17 years · Healthy volunteers
Substances:Pneumococcal Polysaccharide Serotype 3 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
Sponsor:Pfizer Inc.

Contact Research Centre

Meningococcal infection

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of MenACYW Conjugate Vaccine Compared to a Drug Combination in Healthy Infants and Toddlers

Registered drugNo placebo

Poland

Participants:0–17 years · Healthy volunteers
Substances:N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid
Sponsor:Sanofi Pasteur

Contact Research Centre

Respiratory syncytial virus infection

Not recruiting

Registered drug

Study on the Safety and Effectiveness of MK-1654 for Preventing Respiratory Syncytial Virus (RSV) in Healthy Pre-Term and Full-Term Infants

Registered drug

Poland

Participants:0–17 years · Healthy volunteers
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Colitis ulcerative

Not recruiting

Registered drugNo placebo

Study on Vedolizumab for Patients with Active Ulcerative Colitis

Registered drugNo placebo

Poland

Participants:18–64 years · 65+ years
Substances:Vedolizumab
Sponsor:Alimentiv Inc.

Contact Research Centre

Urinary tract infection

Not recruiting

Registered drug

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Cilastatin
Sponsor:Spero Therapeutics Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites